WGN Radio

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...
KRON4 News

REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor ...

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Regeneron is a biotechnology company ...
Seeking Alpha

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support ...
WSPA

REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Regeneron is a biotechnology company ...